Porcine Vaccine Market Growth Trajectory Through 2024-2033

The Porcine Vaccine Global Market Report 2024 by The Business Research Company provides market overview across 60+ geographies in the seven regions – Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa, encompassing 27 major global industries. The report presents a comprehensive analysis over a ten-year historic period (2010-2021) and extends its insights into a ten-year forecast period (2023-2033).

Learn More On The Porcine Vaccine Market:
https://www.thebusinessresearchcompany.com/report/porcine-vaccine-global-market-report

According to The Business Research Company’s Porcine Vaccine Global Market Report 2024, The porcine vaccine market size has grown strongly in recent years. It will grow from $1.74 billion in 2023 to $1.91 billion in 2024 at a compound annual growth rate (CAGR) of 9.5%. The growth in the historic period can be attributed to disease outbreaks and control measures, global increase in pork consumption, intensification of pig farming, government initiatives for disease control, awareness and education programs.

The porcine vaccine market size is expected to see strong growth in the next few years. It will grow to $2.73 billion in 2028 at a compound annual growth rate (CAGR) of 9.4%. The growth in the forecast period can be attributed to global expansion of pig farming, rising disease challenges, stringent regulations and compliance, technological advancements in vaccine development, global trade and disease risk mitigation. Major trends in the forecast period include customization of vaccines for regional challenges, integration of biotechnology in vaccine development, rising concerns about zoonotic diseases, application of genomic approaches in vaccine design, growing investments in research and development.

The increasing infection of swine disease will propel the growth of the porcine vaccine market going forward. Swine influenza (swine flu) is a respiratory illness that affects pigs commonly caused by the type A influenza virus, which frequently causes influenza outbreaks in pigs. Porcine vaccines are instilled into pigs, where the pigs’ immune systems react to the vaccine and recall the pathogenic agent by inducing an immunogenic reaction. These vaccines prepare the swine’s immune system to fight against pathogens and prevent the sickness by exerting an anamnestic reaction when encountering the same pathogen. For instance, in December 2021, according to the report published by Swine Health Information Centre, a US-based agency that protects and enhances the health of swine, European countries registered 1,844 outbreaks of African Swine Fever (ASF) in domestic pigs in the year 2021. Therefore, the rising infection of swine disease is driving the porcine vaccine market.

Get A Free Sample Of The Report (Includes Graphs And Tables):
https://www.thebusinessresearchcompany.com/sample.aspx?id=9111&type=smp

The porcine vaccines market covered in this report is segmented –

1) By Technology: Inactivated Vaccines, Live Attenuated Vaccines, Toxoid Vaccines, Recombinant Vaccines, Conjugate Vaccines, DNA Vaccines
2) By Disease Indication: Diarrhea, Swine Influenza, Arthritis, Bordatella Rhinitis, Porcine Reproductive and Respiratory Virus (PRRSV), Porcine Circovirus Associated Disease (PCVAD), Other Disease Indications
3) By End User: Veterinary Hospitals, Hog or Pig Production Farm

Major companies operating in the porcine vaccine market are developing innovative products, such as the 3-in-one swine vaccine, to provide better protection from various diseases. Swine vaccines are a crucial component of swine health management, aimed at protecting pigs from various diseases. For instance, in June 2023, Merck Animal Health, a US-based pharmaceutical company dedicated to preserving and improving the health, well-being, and performance of animals through science, launched Circumvent CML, a three-in-one vaccine that controls for the diseases Porcine Circovirus Type 2a (PCV-2a), Porcine Circovirus Type 2d (PCV-2d), Mycoplasma hyopneumoniae, and Lawsonia intracellularis. The innovative product gives producers and caregivers piece of mind by providing more convenience and further assurance that supplies are delivered appropriately. Merck’s foundation of well-proven adjuvant systems and tried-and-true antigens serves as the basis for this novel vaccine. Circumvent CML reduces the number of injections for younger pigs and simplifies the vaccination process.

The porcine vaccine market report table of contents includes:

1. Executive Summary
2.Porcine Vaccine  Market Characteristics
3.Porcine Vaccine  Market Trends And Strategies
4.Porcine Vaccine  market analysis
5.Porcine Vaccine  Market Size And Growth
6.Porcine Vaccine  Segmentation
7.Porcine Vaccine  Regional And Country Analysis
.
.
.
27.Porcine Vaccine  Competitive Landscape And Company Profiles
28.Porcine Vaccine  Key Mergers And Acquisitions
29.Porcine Vaccine  Future Outlook and Potential Analysis

TOP MAJOR PLAYERS: